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Background: When assessing pain in clinical practice, clinicians often label pain as mild, 
moderate, and severe. However, these categories are not distinctly defined, and are often 
used arbitrarily. Instruments for pain assessment use more sophisticated scales, such as a 
0–10 numerical rating scale, and apart from pain intensity assess pain-related interference and 
disability. The aim of the study was to identify cutoff points for mild, moderate, and severe 
nondental orofacial pain using a numerical rating scale, a pain-related interference scale, and 
a disability measurement.
Materials and methods: A total of 245 patients referred to the Facial Pain Unit in London 
were included in the study. Intensity and pain-related interference were assessed by the Brief Pain 
Inventory. Pain-related disability was assessed by the Chronic Graded Pain Scale. Average pain 
intensity (0–10) was classified into nine schemes with varying cutoff points of mild, moderate, and 
severe pain. The scheme with the most significant intergroup difference, expressed by multivariate 
analysis of variance, provided the cutoffs between mild, moderate, and severe pain.
Results: The combination that showed the greatest intergroup differences for all patients 
was scheme 47 (mild 1–4, moderate 5–7, severe 8–10). The same combination provided the 
greatest intergroup differences in subgroups of patients with temporomandibular disorder and 
chronic idiopathic facial pain, respectively. Among the trigeminal neuralgia patients alone, the 
combination with the highest intergroup differences was scheme 48 (mild 1–4, moderate 5–8, 
severe 9–10).
Conclusion: The cutoff points established in this study can discriminate in pain intensity 
categories reasonably well, and showed a significant difference in most of the outcome mea-
sures used.
Keywords: chronic orofacial pain, cutoff point, trigeminal neuralgia, temporomandibular 
disorder
Introduction
After the correct diagnosis has been established, a vital step for effective treatment of 
chronic pain is assessment of its intensity and impact. Clinicians most often use cat-
egories like mild, moderate, and severe. The categories are not distinctly defined, and 
are often used arbitrarily. More sophisticated tools like the Brief Pain Inventory (BPI) 
or the Chronic Graded Pain Scale1,2 most often use a 0–10 numeric rating scale (NRS). 
Apart from pain intensity, these instruments assess the degree of pain-related functional 
interference and its impact on quality of life. In spite of the availability of these instru-
ments, many clinicians prefer the use of the mild, moderate, and severe categories.
The question, therefore, arises if it is possible to define more precisely categories 
like mild, moderate, and severe using these instruments. An NRS cannot just be divided Journal of Pain Research 2015:8 submit your manuscript | www.dovepress.com
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into three equal parts, because the relationship between 
pain intensity and functional interference is not linear. The 
reduction in the same interval of intensity on different parts 
of an NRS does not produce similar reduction in functional 
impairment or patient’s general well-being.3 The relationship 
between pain intensity and pain-related interference would 
thus be more correctly defined by identifying cutoff points 
for mild, moderate, and severe pain.
This method, introduced by Serlin et al,3 has been widely 
applied. Cutoff points have been determined for various 
chronic pain conditions, such as cancer pain, diabetic neu-
ropathy, osteoarthritis, low-back pain, phantom limb pain, 
neck pain, and musculoskeletal pain.4–10 In these studies, 
cutoff points for mild pain ranged from 2 to 5, while cutoff 
points for severe pain ranged from 6 to 8. The results of these 
studies suggest that the pain experience and pain-related 
functional impairment depends on the condition and the 
affected site. However, cutoff points for nondental orofacial 
pain have not been identified. Identifying cutoff points for 
mild, moderate, and severe nondental orofacial pain would 
aid clinicians and investigators in defining a measurable target 
range of adequate pain relief. The severity and impact of the 
different orofacial pains is large, especially if rare conditions, 
such as trigeminal neuralgia (TN) and the trigeminal auto-
nomic cephalalgias, are included.11–13 The cutoff points could 
also be used to determine entry into clinical trials.
The aim of this study was to identify cutoff points between 
mild, moderate, and severe non dental orofacial pain, to assess 
if the cutoff points can be generally applied to all nondental 
orofacial pain conditions or if they are specific to each of the 
disorders, and to determine if the cutoff points discriminate 
between three intensity categories in several patient-related 
outcome measures (functional impairment, pain-related dis-
ability, depression, and anxiety).
Materials and methods
The study was reviewed and approved by the European 
Association of Oral Medicine board. All patients referred 
to the national Facial Pain Unit in London during a 6-week 
period in 2009 were asked to participate in the study. The 
Facial Pain Unit sees 700 new patients and 1,400 follow-up 
patients per year, and all patients have previously seen at 
least one primary care provider. 
Criteria for referral to the unit are chronic pain, ie, over 3 
months and exclusion of dental causes. Therefore, a 6-week 
period was assumed to provide a representative sample of 
non dental orofacial pain patients in terms of demographics 
and diagnosis. 
The inclusion criteria were presence of nondental 
  orofacial pain for more than 3 months, age over 18 years, 
and ability to understand questionnaires (one of the essential 
requirements for assessment in the clinic is the completion of 
several questionnaires that assess patients’ treatment expec-
tations, sociodemographic data, pain intensity, pain-related 
interference, and pain-related disability). Theoretically, 
patients who did not understand the questionnaires would 
have been excluded from the study, but this did not occur, 
as the questionnaires were sent out ahead of the appointment 
and patients were encouraged to ask for help if they had dif-
ficulties completing them. Fifteen however did not complete 
all the questions, and so were excluded. 
Demographic and clinical data (age, sex, duration of 
pain, and number of specialists seen before referral to the 
Facial Pain Unit) were registered. Intensity and pain-related 
functional impairment were assessed by the BPI.1 The BPI 
uses an eleven-item NRS (0–10), where patients rate their 
worst, least, average, and current pain intensity, as well as 
interference with various aspects of everyday life (general 
activity, mood, walking, work, relationships with other 
people, sleep, and enjoyment in life). Pain-related disabil-
ity was assessed by the Chronic Graded Pain Scale.2 This 
classifies patients into four disability categories (1, low 
intensity, low disability; 2, high intensity, low disability; 3, 
high disability, moderately limiting; and 4, high disability, 
severely limiting) based on interference with everyday 
activity and period of limited activity because of pain. The 
Hospital Anxiety and Depression Scale (HADS) was used 
to assess anxiety and depression.14 According to the HADS 
score, patients were classified as follows: 0–7, no depres-
sion/anxiety; 8–10, borderline depression/anxiety; and 11 
and over, depression/anxiety.
Patients were classified into three subgroups according 
to their diagnosis: all types of TN, myogenic temporoman-
dibular disorder (TMD) and persistent/chronic idiopathic 
facial pain (CIFP). TN was diagnosed according to the 
International Classification of Headache Disorders criteria.15 
The diagnosis of TMD was made according to the following 
criteria: 1) pain and tenderness of the muscles of mastica-
tion of 3 months’ duration or longer and 2) no clinical and/
or radiographic evidence of organic temporomandibular 
joint disorder.16 The third group was heterogeneous, and 
consisted of patients who did not fit into the previous two 
groups (patients with CIFP, burning mouth syndrome, and 
posttraumatic neuropathic pain). The diagnoses of these 
were made according to the International Classification of 
Headache Disorders criteria.15Journal of Pain Research 2015:8 submit your manuscript | www.dovepress.com
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statistical analysis
SPSS software (version 20 for Windows; IBM, USA) was used 
for data analysis. Depending on the distribution of the data, 
mean and standard deviation or median and range were used 
to summarize the data. For categorical variables, differences 
between groups were tested by the χ2 test. For numerical vari-
ables, group differences were assessed by one-way analysis of 
variance (ANOVA), followed by post hoc Bonferroni test or 
the Kruskal–Wallis test followed by Mann–Whitney U tests, 
with P-values adjusted for multiple testing if the assumptions 
of the ANOVA were not satisfied.
Determination of cutoff points was performed as described 
by Serlin et al.3 Average pain intensity was classified into nine 
schemes with different cutoff points of mild, moderate and 
severe pain: 1, scheme 35 (mild 1–3, moderate 4–5, severe 
6–10); 2, scheme 36 (mild 1–3, moderate 4–6, severe 7–10); 
3, scheme 37 (mild 1–3, moderate 4–7, severe 8–10); 4, 
scheme 38 (mild 1–3, moderate 4–8, severe 9–10); 5, scheme 
46 (mild 1–4, moderate 5–6, severe 7–10); 6, scheme 47 
(mild 1–4, moderate 5–7, severe 8–10); 7, scheme 48 (mild 
1–4, moderate 5–8, severe 9–10); 8, scheme 57 (mild 1–5, 
moderate 6–7, severe 8–10); and 9, scheme 58 (mild 1–5, 
moderate 6–8, severe 9–10). Nine multivariate one-way 
ANOVAs were performed, with the intensity group (mild, 
moderate, and severe) as the independent variable and seven 
pain-interference domains from the BPI as the dependent 
variable. The scheme with the most significant intergroup 
difference, expressed by the smallest P-value determined 
from Wilks’ lambda, was considered to indicate the maximum 
difference between the groups, and thus provided the cutoffs 
between mild, moderate, and severe pain.
To assess if the determined cutoff points discriminated 
adequately between pain-intensity categories, patients were 
compared on various outcome measures using one-way 
ANOVAs, followed by Bonferroni post hoc comparisons 
where appropriate (for pain-related interference), or χ2 tests 
(for pain-related disability, depression, and anxiety). In all 
analyses, P,0.01 was considered statistically significant. 
This significance level was chosen rather than the conven-
tional 0.05 level to avoid spuriously significant results arising 
from multiple testing. Effect size was expressed by η2 or 
ϕ-coefficient where appropriate.
Results
Demographic and clinical  
characteristics of the participants
A total of 245 patients were included in the study. There 
were 186 (76%) female patients and 59 (24%) male patients. 
A total of 112 patients had TMD, 85 patients had CIFP, and 
48 patients had TN. The median age of the participants was 
47 (range 18–84) years. The demographic and clinical data 
of the patients are shown in Table 1.
No significant difference in sex was observed between the 
three groups of patients. A significant difference in median 
age was observed between the groups: TN patients were 
significantly older than CIFP and TMD patients (P=0.002 
and P,0.001, respectively). CIFP patients were on aver-
age significantly older than patients with TMD (P,0.001). 
Median duration of pain was significantly longer in TN 
patients compared to TMD and CIFP patients (P,0.001 
and P=0.027, respectively). TN and CIFP patients visited 
significantly more pain specialists before referral to the 
Facial Pain Unit than TMD patients (P=0.004 and P,0.001, 
respectively). No significant difference in the proportion of 
patients with anxiety and depression was found between the 
three groups of participants.
The mean value of the average pain intensity was sig-
nificantly higher in CIFP patients than in TMD patients 
(P=0.003). No significant differences in the mean values 
of average pain intensity were observed between TMD and 
TN patients or CIFP and TN patients (P=0.999 and P=0.186, 
respectively). No significant differences were observed 
in the mean worst, least, and current pain-intensity scores 
between three groups of participants (P=0.081, P=0.025, 
and P=0.097, respectively). No significant differences in 
pain-related interference were observed between the three 
groups of participants (P=0.058). No significant differences 
in pain-related disability were observed between the three 
groups of participants (P=0.206).
Determination of cutoff points
Cut-off points were determined as described in the Materi-
als and methods section. The combination that showed the 
greatest intergroup differences for all patients was scheme 
47 (mild 1–4, moderate 5–7, severe 8–10). The same com-
bination provided the greatest intergroup differences in 
TMD and CIFP patients. Among the TN patients alone, the 
combination with the highest intergroup differences was 
scheme 48 (mild 1–4, moderate 5–8, severe 9–10) (Table 2). 
No significant difference in cutoff points between males and 
females was observed. (η2 ranged from 0.35 – 0.41, indicat-
ing strong effect).
assessment of cutoff points
As explained in the Materials and methods section, in order 
to assess if the optimal cutoff points discriminated between Journal of Pain Research 2015:8 submit your manuscript | www.dovepress.com
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the pain-intensity categories, the three intensity groups were 
compared on various outcome measures using univariate one-
way ANOVAs, followed by Bonferroni post hoc comparisons 
where appropriate (pain-related interference), or χ2 tests 
(pain-related disability, depression, and anxiety).
Pain interference in pain-intensity groups
In all patients, a significant difference in the means between 
mild-, moderate-, and severe-pain categories was found for 
all BPI interference scales, as well as for overall interference 
(Figure 1); η2 ranged from 0.26 to 0.57, indicating a strong 
effect. In the subgroup of TMD patients, a significant differ-
ence between mild, moderate, and severe pain was found for 
all BPI interference scales, as well as for overall interference. 
A post hoc test did not reveal significant difference in 
interference with walking ability among patients with mild 
and moderate pain (P=0.286); η2 ranged from 0.22 to 0.61, 
indicating a moderate-to-strong effect. In the subgroup of 
CIFP patients, a significant difference between mild, mod-
erate, and severe pain was found for all BPI interference 
scales, as well as for overall interference. A post hoc test did 
not reveal a significant difference in interference with work 
among patients with moderate and severe pain (P=0.228); 
η2 ranged from 0.24 to 0.48, indicating moderate-to-strong 
effect. In the subgroup of TN patients, a significant difference 
between mild, moderate, and severe pain was observed for 
all BPI interference scales, as well as for overall interference. 
Post hoc tests did not reveal significant differences in inter-
Table 1 Demographic and clinical data of the patients
Total TMD CIFP TN P
Sex, n (%) χ2
Female 186 (76%) 90 (80.4%) 63 (74.1%) 33 (70.2%) 0.333
Male 59 (24%) 22 (19.6%) 22 (25.9%) 15 (29.8%)
Total 245 112 85 48
Mann–Whitney U
Age, years, median (range) 47 (12–84) 36.5 (12–77) 50 (23–84) 64 (20–81) ,0.001*
Duration of pain, months, median (range) 27 (6–468) 24 (6–180) 36 (6–360) 64 (6–468) ,0.001*
Referred by, n (%) χ2
gDP 71 (41%) 37 (52.1%) 27 (37.5%) 7 (23.3%) 0.051
gMP 43 (24.9%) 18 (25.4%) 15 (20.8%) 10 (33.3%)
specialist 59 (34.1%) 16 (22.5%) 30 (41.7%) 13 (43.3%)
Mann–Whitney U
number of specialists visited before the  
referral, median (range)
2 (0–7) 1 (0–6) 2 (0–7) 2 (0–5) ,0.001*
Depression, n (%) χ2
none 60 (52.2%) 41 (67.2%) 15 (57.7%) 19 (67.9%) 0.140
Borderline/mild depression 25 (21.7%) 12 (19.7%) 3 (11.5%) 7 (25%)
severe depression 30 (26.1%) 8 (13.1%) 8 (30.8%) 2 (7.1%)
Anxiety, n (%) χ2
none 75 (65.2%) 27 (44.3%) 16 (61.5%) 17 (60.7%) 0.493
Borderline/mild anxiety 22 (19.1%) 16 (26.2%) 4 (15.4%) 5 (17.9%)
severe anxiety 18 (15.7%) 18 (29.5%) 6 (23.1%) 6 (21.4%)
Pain intensity, mean ± SD Analysis of variance
average 4.9±2.9 4.3±2.7 5.7±2.8 5.2.±3.2 0.004*
Worst 5.7±3.2 5.2±3.2 6.2±3 6±3.4 0.081
least 3.5±3.1 3±2.9 4.2±3.1 3.8±3.6 0.025
current 4.1±3.2 3.7±3.1 4.7±3.1 4±3.5 0.097
Pain-related interference, mean ± sD 3.7±2.9 3.3±2.8 4.3±3 3.8±3 0.055
Pain-related disability, n (%) χ2
grade 1 64 (28.1%) 38 (36.9%) 16 (21.3%) 10 (20%) 0.206
grade 2 62 (27.2%) 28 (27.2%) 22 (29.3%) 12 (24%)
grade 3 35 (15.4%) 14 (13.6%) 14 (18.7%) 7 (14%)
grade 4 67 (29.3%) 23 (22.3%) 23 (30.7%) 21 (42%)
Notes: *P,0.01. Specialist – health care professional with dental or medical specialization; number of specialists visited before the referral, number of medical and/or dental 
specialists that patient saw before he/she was referred to the Facial Pain Unit; pain intensity (average, worst, least, right now), intensity subscales of the Brief Pain Inventory; 
pain-related interference, overall interference calculated from the interference subscales of the Brief Pain Inventory; pain-related disability determined by the Chronic Graded 
Pain scale.
Abbreviations: TMD, temporomandibular disorder; CIFP, chronic idiopathic facial pain; TN, trigeminal neuralgia; SD, standard deviation; GDP, general dental practitioner; 
GMP, general medical practitioner.Journal of Pain Research 2015:8 submit your manuscript | www.dovepress.com
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ference with mood or   enjoyment of life among patients 
with moderate and severe pain (P=0.786 and P=0.270, 
respectively). Furthermore, in the TN subgroup, nonsig-
nificant differences in interference with walking ability and 
sleep were found between patients with mild and moderate 
pain (P=0.366 and P=0.318, respectively); η2 ranged from 
0.3 to 0.56, indicating a strong effect.
Pain-related disability  
in pain-intensity groups
A significant association was found between intensity of pain 
(mild, moderate and severe pain) and pain-related disability. 
Statistical significance was observed in all patients, as well 
as in all three subgroups of patients (P,0.001, P,0.001, 
P,0.001, and P=0.005, respectively); ϕ-values ranged from 
0.66 to 0.73, indicating a strong effect (Figure 2).
Depression and anxiety  
in pain-intensity groups
A significant association was observed between pain intensity 
(mild, moderate, and severe pain) and anxiety (P=0.008) in 
all patients. No significant association was observed between 
pain intensity and depression and P=0.014 in any patients. 
  Significant differences in the percentage of anxiety and depres-
sion among patients with mild, moderate, and severe pain 
were found in the TMD (P,0.001 and P,0.001, respectively) 
and TN subgroups (P,0.001 and P,0.001, respectively). 
No significant difference in the percentages of either anxiety 
or depression between patients with mild, moderate, and 
severe pain was observed in the CIFP subgroup (P=0.141 and 
P=0.175, respectively) (Figure 3); ϕ-values ranged from 0.34 
to 1 indicating a moderate-to-strong effect.
Discussion
The results of this study indicate that in nondental orofacial 
pain conditions, the reduction in equal interval of pain inten-
sity on an NRS will not produce the same level of reduction 
in functional impairment. This finding confirms the nonlinear 
relationship between pain intensity and functional impair-
ment, as suggested by Serlin et al.3 Using the eleven-item 
NRS, intensity of nondental orofacial pain can be defined 
as follows: mild pain 0–4, moderate pain .4–7, and severe 
pain .7–10. Cutoff points established in this way provide 
significant differences for almost all outcome measures used 
in this study, which is especially emphasized in the overall 
pain-related interference and pain-related disability. This 
combination of cutoff points was found to be optimal also 
for phantom limb pain, peripheral diabetic neuropathy, knee 
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Figure 1 Pain-related interference in the three pain-intensity groups.
Abbreviations: TMD, temporomandibular disorder; CIFP, chronic idiopathic facial pain; TN, trigeminal neuralgia; SD, standard deviation.
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osteoarthritis, and cancer pain.5–8 Chronic pain conditions 
like back pain, general pain, neck pain, and headache had 
different combinations of optimal cutoff points.4,6,17 These 
findings indicate that the impact of chronic pain on daily 
activities does not depend solely on the pain intensity, but is 
also dependent on the nature of the condition.
Demographic factors, such as sex and age, did not 
affect the established cutoff points. It is known that chronic Journal of Pain Research 2015:8 submit your manuscript | www.dovepress.com
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orofacial pain conditions, such as TN, TMD, and CIFP, are 
more prevalent among women. Women tend to report higher 
pain intensity and duration of pain.18,19 However, no difference 
between men and women was found in any of the studies 
that determined cutoff points for mild, moderate, and severe 
pain in different chronic pain conditions.4–10 It seems that the 
impact of pain on everyday function diminishes sex-related 
differences in pain perception. There are no studies that 
compare pain intensity in different age-groups for CIFP and 
TN. The exception is TMD, where pain intensity appears to 
decrease with age of 60 years and over.20–22
Even though anxiety and depression are often found in 
chronic pain, their relationship is not linear.23–25 Anxiety and 
depression depend not only on pain intensity but also on other 
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factors, such as pain acceptance, individual coping strategies, 
and other risk factors.26–28 A significant difference between 
the three pain-intensity groups was found only for TMD and 
TN patients. The difference was not statistically significant 
in the CIFP group, which could be due to heterogeneity of 
the group or the aforementioned mentioned pain acceptance 
and individual coping strategies. Anxiety and depression 
were used for the comparison of intensity groups in only 
two studies that used the same method for the identification 
of cutoff points in chronic pain.5,8 Paul et al did not find sig-
nificant difference in either depression or anxiety between 
cancer patients classified as having mild, moderate, and 
severe pain.8 On the other hand, in a study of Hoffman et al, 
anxiety and depression subscales discriminated significantly 
between pain-intensity subgroups in patients with diabetic 
neuropathy.5 The difference between the studies could have 
been due to the use of different scales for the assessment of 
depression and anxiety: Paul et al used the shortened version 
of the Profile of Mood States, while Hoffmann et al used the 
HADS.5,8 In spite of the differences, it remains important 
to monitor patients’ psychological health, as chronic pain 
is a risk factor for the onset of anxiety and/or depressive 
disorders.23–25
Cutoff points are not characteristic for an individual 
condition, but can be used in almost all nondental chronic 
orofacial pain conditions. The exception was TN patients, 
where the highest intergroup difference was obtained in 
scheme 48 (mild pain 1–4, moderate .4–8, severe .8–10). 
There can be several reasons for this. First of all, the group 
of TN patients was very small, and the statistical analysis 
could have been affected by the subtle changes in the num-
ber of patients in intensity-level subgroups. On the other 
hand, these results could reflect the character of TN. Despite 
high pain intensity, the pain in TN is episodic, and higher 
pain intensity and longer duration may be needed to result 
in a meaningful interference with daily activities. Further-
more, in the majority of TN patients, pain can be adequately 
controlled with medications that can have a positive impact 
on pain-related interference with daily activities.30 Having 
experienced very severe episodes of pain, patients with TN 
may be more discriminating about their pain severity, ie, 
they often distinguish between what they term “twinges” 
compared to “electric shocks”. Unlike TN, in TMD and 
CIFP the pain is more or less constant and often not success-
fully controlled with medications that can affect patients’ 
daily activities and quality of life. Furthermore, patients 
with TMD and CIFP are more likely to have other chronic 
pain and more psychosocial predisposing factors than TN 
patients, and so require a holistic treatment approach.31–36 
Only 17% of the TN patients in this cohort compared to 
90% of patients in the TMD and CIFP subgroups had other 
chronic pain including headache. This might explain why 
lower pain intensity can result in higher disability/functional 
impairment.
Classification of mild, moderate, and severe pain as 
defined in this study is in line with patients’ definition of 
acceptable outcome. According to the studies of Thorne 
and Morley37 and Farrar et al38 on more than 2,000 patients 
with various chronic pain conditions, patients’ definition of 
“much improvement” implies reduction of 2–3 raw points 
or 30% on an NRS. In TMD patients, clinically important 
change was defined as an intensity visual analog scale score 
reduction of 19.5 mm and percentage change of 37.9% from 
baseline.39 Percentage change showed higher sensitivity, since 
raw visual analog scale score reduction was significantly 
affected by the baseline pain levels.39 Furthermore, the Ini-
tiative on Methods, Measurement and Pain Assessment in 
Clinical Trials (IMMPACT) recommends reporting on the 
percentages of patients achieving $30% reduction in the 
NRS, since this reduction appears to reflect at least moder-
ate clinically important difference.40 Reduction of $50%, on 
the other hand, reflects substantial improvement and should 
also be reported. This is especially relevant in TN, where 
unlike other types of nondental orofacial pain, nearly 100% 
pain reduction can be achieved; if not by medication, then 
by surgery.41
This study has several limitations that need to be addressed. 
According to Hirschfeld and Zernikow, the statistical method 
for determination of cutoff points applied in this study does not 
take into account the variability of the sample.17 The authors 
state that the differences between the groups were as a result of 
a chance variation rather than true differences in pain-related 
interference. Bootstrapping was performed, the rank ordering 
of the cut-off points was not affected, and the combination of 
47 and 48 was still identified as the most appropriate for TMD, 
CIFP, and TN. The cutoff points could not represent the optimal 
relationship between pain intensity and functional interference 
in every individual patient, but for the majority of nondental 
orofacial pain patients, these measures are probably valid. 
Furthermore, one of the pain characteristics not assessed in 
the BPI that could be of importance is interference with eating. 
This characteristic would probably be emphasized in non-
dental chronic orofacial pain and might influence the results. 
An extended BPI, called BPI facial, which includes seven 
additional oral/facial parameters, has recently been validated 
in patients with TN.42 However, no data are yet available on its Journal of Pain Research 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
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validity in other facial pain conditions. Therefore, we decided 
to use a validated instrument, as was used in all similar stud-
ies.3–10 Another limitation of this study is the small number of 
TN patients. Further studies with larger numbers of patients 
are therefore required.
In spite of the study limitations, we believe that the cutoff 
points determined in this study discriminate pain-intensity 
categories reasonably well and provide significant   difference 
in most of the outcome measures used. These cutoff points 
would help clinicians and researchers to define more precisely 
satisfactory levels of pain relief in nondental orofacial pain 
patients. They would be of use in clinical trials and for pro-
viders of pain services when assessing pain-related outcome 
measures.
Acknowledgments
We are grateful to Aviva Petrie and David Boniface, who 
advised on the statistical analysis. VB undertook this 
work as part of his grant from the European Association 
of Oral Medicine. JMZ undertook this work at UCL/
UCLHT, who received a proportion of funding from 
the Department of Health’s NIHR Biomedical Research 
Centre funding.
Author contributions
Both authors collected the data and contributed to the 
manuscript equally. Both authors discussed the results and 
commented on the manuscript.
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain 
Inventory. Ann Acad Med Singapore. 1994;23(2):129–138.
2.  Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of 
chronic pain. Pain. 1992;50(2):133–149.
3.  Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When 
is cancer pain mild, moderate or severe? Grading pain severity by its 
interference with function. Pain. 1995;61(2):277–284.
4.  Fejer R, Jordan A, Hartvigsen J. Categorising the severity of neck pain: 
establishment of cut–points for use in clinical and epidemiological 
research. Pain. 2005;119(1–3):176–182.
5.  Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain 
severity levels correspond to changes in health status and function in 
patients with painful diabetic peripheral neuropathy? Pain. 2010;149(2): 
194–201.
6.  Jensen MP, Smith DG, Ehde DM, Robinsin LR. Pain site and the effects 
of amputation pain: further clarification of the meaning of mild,   moderate, 
and severe pain. Pain. 2001;91(3):317–322.
7.  Kapstad H, Hanestad BR, Langeland N, Rustøen T, Stavem K. Cutpoints 
for mild, moderate and severe pain in patients with osteoarthritis of the 
hip or knee ready for joint replacement surgery. BMC Musculoskelet 
Disord. 2008;9:55.
  8.  Paul SM, Zelman DC, Smith M, Miaskowski C. Categorizing the 
  severity of cancer pain: further exploration of the establishment of 
cutpoints. Pain. 2005;113(1–2):37–44.
  9.  Zelman DC, Dukes E, Brandenburg N, Bostrom A, Gore M. 
  Identification of cut-points for mild, moderate and severe pain due to 
diabetic peripheral neuropathy. Pain. 2005;115(1–2):29–36.
  10.  Zelman DC, Hoffman DL, Seifeldin R, Dukes EM. Development of a 
metric for a day of manageable pain control: derivation of pain severity 
cut-points for low back pain and osteoarthritis. Pain. 2003;106(1–2): 
35–42.
  11.  Conti PC, Pinto-Fiamengui LM, Cunha CO, Conti AC. Orofacial pain 
and temporomandibular disorders: the impact on oral health and quality 
of life. Braz Oral Res. 2012;26 Suppl 1:120–123.
  12.  Tölle T, Dukes E, Sadosky A. Patient burden of trigeminal neuralgia: 
results from a cross-sectional survey of health state impairment and 
treatment patterns in six European countries. Pain Pract. 2006;6(3): 
153–160.
  13.  Pigg M, Svensson P, Drangsholt M, List T. Seven-year follow-up 
of patients diagnosed with atypical odontalgia: a prospective study.   
J Orofac Pain. 2013;27(2):151–164.
  14.  Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. 
Acta Psychiatr Scand. 1983;67(6):361–370.
  15.  Headache Classification Subcommittee of the International Headache 
Society. The International Classification of Headache Disorders: 2nd 
edition. Cephalalgia. 2004;24 Suppl 1:9–160.
  16.  Van Grootel RJ, van der Bilt A, van der Glas HW. Long-term reli-
able change of pain scores in individual myogenous TMD patients. 
Eur J Pain. 2007;11(6):635–643.
  17.  Hirschfeld G, Zernikow B. Variability of “optimal” cut points for mild, 
moderate, and severe pain: neglected problems when comparing groups. 
Pain. 2013;154(1):154–159.
  18.  Cairns BE. The influence of gender and sex steroids on craniofacial 
nociception. Headache. 2007;47(2):319–324.
  19.  Paller CJ, Campbell CM, Edwards RR, Dobs AS. Sex-based differences 
in pain perception and treatment. Pain Med. 2009;10(2):289–299.
  20.  Carlsson GE, Ekbäck G, Johansson A, Ordell S, Unell L. Is 
there a trend of decreasing prevalence of TMD-related symp-
toms with ageing among the elderly? Acta Odontol Scand. 
2014;72(8):714–720.
  21.  Johansson A, Unell L, Carlsson GE, Söderfeldt B, Halling A. Risk 
factors associated with symptoms of temporomandibular disorders in a 
population of 50- and 60-year-old subjects. J Oral Rehabil. 2006;33(7): 
473–481.
  22.  Komiyama O, Obara R, Iida T, et al. Age-related associations between 
psychological characteristics and pain intensity among Japanese 
patients with temporomandibular disorder. J Oral Sci. 2014;56(3): 
221–225.
  23.  Gerrits MM, van Oppen P, van Marwijk HW, Penninx BW, van der 
Horst HE. Pain and the onset of depressive and anxiety disorders. Pain. 
2014;155(1):53–59.
  24.  De Heer EW, Gerrits MM, Beekman AT, et al. The association of 
depression and anxiety with pain: a study from NESDA. PLoS One. 
2014;9(10):e106907.
  25.  Gerrits MM, Vogelzangs N, van Oppen P, van Marwijk HW, van der 
Horst H, Penninx BW. Impact of pain on the course of depressive and 
anxiety disorders. Pain. 2012;153(2):429–436.
  26.  McCracken LM. Learning to live with the pain: acceptance of pain predicts 
adjustment in persons with chronic pain. Pain. 1998;74(1): 21–27.
  27.  McCracken LM, Eccleston C. Coping or acceptance: what to do about 
chronic pain? Pain. 2003;105(1–2):197–204.
  28.  McCracken LM, Vowles KE, Eccleston C. Acceptance of chronic 
pain: component analysis and a revised assessment method. Pain. 
2004;107(1–2):159–166.
  29.  Shacham S. A shortened version of the Profile of Mood States. J Pers 
Assess. 1983;47(3):305–306.
  30.  Zakrzewska JM, Linskey ME. Trigeminal neuralgia. BMJ. 2014; 
348:g474.Journal of Pain Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/journal-of-pain-research-journal
The Journal of Pain Research is an international, peer-reviewed, open 
access, online journal that welcomes laboratory and clinical findings 
in the fields of pain research and the prevention and management 
of pain. Original research, reviews, symposium reports, hypoth-
esis formation and commentaries are all considered for publication.   
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Journal of Pain Research 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
104
Brailo and Zakrzewska
  31.  Komiyama O, Wang K, Svensson P, Arendt-Nielsen L, Kawara M, De 
Laat A. The influence of psychological state on the masseteric exterocep-
tive suppression reflex and somatosensory function. Clin Neurophysiol. 
2008;119(10):2321–2328.
  32.  Komiyama O, Obara R, Uchida T, et al. Pain intensity and psychosocial 
characteristics of patients with burning mouth syndrome and trigeminal 
neuralgia. J Oral Sci. 2012;54(4):321–327.
  33.  Wong WS, Chen PP, Yap J, Mak KH, Tam BK, Fielding R. Assessing 
depression in patients with chronic pain: a comparison of three rating 
scales. J Affect Disord. 2011;133(1–2):179–187.
  34.  Yap AU, Tan KB, Chua EK, Tan HH. Depression and somatization 
in patients with temporomandibular disorders. J Prosthet Dent. 
2002;88(5):479–484.
  35.  Yap AU, Chua EK, Hoe JK. Clinical TMD, pain-related disability and 
psychological status of TMD patients. J Oral Rehabil. 2002;29(4): 
374–380.
  36.  Yap AU, Dworkin SF, Chua EK, List T, Tan KB, Tan HH. Prevalence 
of temporomandibular disorder subtypes, psychologic distress, and 
psychosocial dysfunction in Asian patients. J Orofac Pain. 2003;17(1): 
21–28.
  37.  Thorne FM, Morley S. Prospective judgments of acceptable outcomes 
for pain, interference and activity: patient-determined outcome criteria. 
Pain. 2009;144(3):262–269.
  38.  Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical 
importance of changes in chronic pain intensity measured on an 11-point 
numerical pain rating scale. Pain. 2001;94(2):149–158.
  39.  Emshoff R, Emshoff I, Bertram S. Estimation of clinically important 
change for visual analog scales measuring chronic temporomandibular 
disorder pain. J Orofac Pain. 2010;24(3):262–269.
  40.  Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures 
for chronic pain clinical trials: IMMPACT recommendations. Pain. 
2005;113(1–2):9–19.
  41.  Zakrzewska JM, Jassim S, Bulman JS. A prospective, longitudinal study 
on patients with trigeminal neuralgia who underwent   radiofrequency 
thermocoagulation of the gasserian ganglion. Pain. 1999;79(1): 
51–58.
  42.  Lee JY, Chen HI, Urban C, et al. Development of and psychometric 
testing for the Brief Pain Inventory-Facial in patients with facial pain 
syndromes. J Neurosurg. 2010;113(3):516–523.